# A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis

> **NCT01465763** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 614 (actual)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** tofacitinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01465763
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04
- **Primary completion:** 2015-05
- **Final completion:** 2015-05
- **Target enrollment:** 614 (ACTUAL)
- **Last updated:** 2016-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01465763

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01465763, "A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01465763. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*